232 related articles for article (PubMed ID: 27156362)
1. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.
Blau IW; Conlon N; Petermann R; Nikolov N; Plesner T
Expert Rev Clin Immunol; 2016 Jul; 12(7):705-11. PubMed ID: 27156362
[TBL] [Abstract][Full Text] [Related]
2. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.
Dimou M; Iliakis T; Maltezas D; Bitsani A; Kalyva S; Koudouna A; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
Anticancer Res; 2018 Jul; 38(7):4187-4191. PubMed ID: 29970548
[TBL] [Abstract][Full Text] [Related]
3. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
Agostini C; Blau IW; Kimby E; Plesner T
Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
[TBL] [Abstract][Full Text] [Related]
6. Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
Erbaş Açıcı N; Topyildiz E; Aygün A; Geyik M; Edeer Karaca N; Aksu G; Kutukculer N
Int Arch Allergy Immunol; 2024; 185(4):382-391. PubMed ID: 38246144
[TBL] [Abstract][Full Text] [Related]
7. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
[No Abstract] [Full Text] [Related]
8. Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule.
Hustad NB; Degerud HM; Hjelmerud I; Fraz MSA; Nordøy I; Trøseid M; Fevang B; Aukrust P; Jørgensen SF
Front Immunol; 2021; 12():670547. PubMed ID: 34012453
[TBL] [Abstract][Full Text] [Related]
9. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
[TBL] [Abstract][Full Text] [Related]
10. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
[TBL] [Abstract][Full Text] [Related]
11. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
Front Immunol; 2020; 11():981. PubMed ID: 32670265
[TBL] [Abstract][Full Text] [Related]
12. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients.
Paassen PV; Pittrow D; Scheidegger C; Klotsche J; Ellerbroek PM
Immunotherapy; 2020 Feb; 12(2):131-139. PubMed ID: 32066296
[No Abstract] [Full Text] [Related]
13. Intravenous and subcutaneous immunoglobulin G replacement therapy.
Bonilla FA
Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
16. Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.
Li Z; Follman K; Freshwater E; Engler F; Yel L
J Clin Immunol; 2023 Nov; 43(8):2127-2135. PubMed ID: 37773562
[TBL] [Abstract][Full Text] [Related]
17. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology.
Shah N; Mustafa SS; Vinh DC
Crit Rev Oncol Hematol; 2023 Jan; 181():103896. PubMed ID: 36528276
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.
Wasserman RL
Immunotherapy; 2017 Sep; 9(12):1035-1050. PubMed ID: 28871852
[TBL] [Abstract][Full Text] [Related]
19. Why I use subcutaneous immunoglobulin (SCIG).
Shapiro RS
J Clin Immunol; 2013 Jan; 33 Suppl 2():S95-8. PubMed ID: 23264027
[TBL] [Abstract][Full Text] [Related]
20. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
Speth F; Haas JP; Hinze CH
Pediatr Rheumatol Online J; 2016 Sep; 14(1):52. PubMed ID: 27623619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
